The incidence of esophageal and junctional cancer has been increasing in western industrialized nations in the past 30 years. At the time of diagnosis, approximately 50% of patients with esophageal and junctional cancers have distant metastases and are considered incurable. In the recent ESMO guidelines and the German S3 guidelines, surgical therapy for metastatic disease is not recommended. In spite of these recommendations, the treatment of limited metastatic (oligo-metastastic) esophagogastric cancer is currently undergoing a shift towards a more aggressive therapy. Selected patients with oligo-metastatic disease may be considered for surgical resection of the primary tumor and the metastases after chemo(radio)therapy and careful evaluation in an interdisciplinary tumor board. We discuss in this review the literature and some guidelines for extended surgical approaches is laid out. In the future, randomized prospective studies like the German RENAISSANCE/FLOT5 trial and the French SURGIGAST trial will feed us with more evidence if multimodal therapy including surgery for limited metastatic disease is indicated.

Additional Metadata
Keywords Esophageal cancer, Esophagogastric junction adenocarcinoma, Metastasectomy, Metastasis, Multimodal therapy, Oligometastases
Persistent URL dx.doi.org/10.1016/j.bpg.2018.11.002, hdl.handle.net/1765/113763
Journal Best Practice and Research in Clinical Gastroenterology
Citation
Mönig, S. (Stefan), van Hootegem, S. (Sander), Chevallay, M. (Mickael), & Wijnhoven, B.P.L. (2018). The role of surgery in advanced disease for esophageal and junctional cancer. Best Practice and Research in Clinical Gastroenterology (Vol. 36–37, pp. 91–96). doi:10.1016/j.bpg.2018.11.002